Does adjuvant trastuzumab improve disease-free survival with acceptable cardiac safety in breast cancer patients?
Adjuvant trastuzumab is recommended for eligible breast cancer patients due to its disease-free survival benefit and low, potentially reversible risk of cardiac dysfunction.
Given the clear benefit in disease-free survival, the low incidence of cardiac adverse events, and the suggestion that cardiac dysfunction might be reversible, adjuvant trastuzumab should be considered for treatment of breast cancer patients who fulfill the HERA trial eligibility criteria.
Suter et al. (2007) studied this question.